ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

datopotamab deruxtecan

Also written as “Dato-DXd”, “Datopotamab deruxtecan” and “Datopotamab Deruxtecan”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Triple Negative Breast Neoplasms · Endometrial Neoplasms · Urinary Bladder Neoplasms, led by 2 companies.

Drug pageDatopotamab deruxtecan: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 4, 202129 company-led studies, 28 open or runningCo-development: Daiichi Sankyo and AstraZeneca, Jul 2020Next primary completion: Jan 11, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only2121 open or runningphase 3since Oct 4, 2021Oct 25, 2018Jan 11, 2027phase 3 · NCT06417814
Daiichi Sankyo87 open or runningphase 3since Nov 19, 2020Jan 9, 2018Jan 1, 2028phase 1 · NCT03401385

Also a collaborator on its studies: Merck and Parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2018First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT03401385 · 890 enrolled · United States, Japan
  2. Dec 9, 2019Named datopotamab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 122
  3. Jul 20, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04484142 · 137 enrolled · United States, France, Germany and more
  4. Jul 27, 2020AstraZeneca develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Daiichi Sankyo and AstraZeneca (release)
  5. Aug 21, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04526691 · 145 enrolled · United States, Italy, Japan and more
  6. Nov 19, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04656652 · 605 enrolled · United States, Argentina, Australia and more
  7. Jan 18, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05215340 · 740 enrolled · United States, Argentina, Australia and more
  8. Sep 22, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05555732 · 1,233 enrolled · United States, Argentina, Australia and more
  9. Aug 12, 2025Phase 3 study in Urinary Bladder NeoplasmsNCT07129993 · 630 planned · United States, Austria, China and more
  10. Oct 16, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07890714 · 268 planned · Taiwan

Ahead

  1. Jan 1, 2028Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT03401385
  2. May 11, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05555732
  3. Jun 1, 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsNCT07129993
  4. Sep 30, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07890714

TargetBeta

TACSTD2 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (calcium signal transducer 2; TROP2; TROP-2; TACSTD2) ”NCIt, by rule
“Tumor-associated calcium signal transducer 2 binding agent”ChEMBL 37, by rule

Other programs on TACSTD2

ProgramCompanyFurthest phaseStudies
sacituzumab govitecanruleGilead Sciencesphase 430
sacituzumab tirumotecanMerckphase 350
JSKN016ruleAlphamab Oncologyphase 35
Anti-TROP2 Antibody-drug Conjugate ESG401ruleQilu Pharmaceuticalphase 33
Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036CruleMinghui Pharmaceuticalphase 23
sacituzumab drozuntecanruledualitybio-incphase 22
Anti-TROP-2 Antibody-drug Conjugate OBI-902ruleobi-pharma-incphase 21
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruleAstellas Pharmaphase 21
JSKN016HCruleAlphamab Oncologyphase 11
KH815ruleChengdu Kanghong Pharmaceutical Groupphase 11

Studies

All 8 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07890714Carcinoma, Non-Small-Cell Lung · Taiwan2RecruitingSep 30, 2029268
NCT07129993Urinary Bladder Neoplasms · United States, Austria, China and more3RecruitingJun 1, 2029630
NCT05555732Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMay 11, 20291,233
NCT05215340Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMar 4, 2030740
NCT04656652Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingMay 10, 2024605
NCT04526691Carcinoma, Non-Small-Cell Lung · United States, Italy, Japan and more1Active, not recruitingApr 14, 2024145
NCT04484142Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more2CompletedMar 10, 2023137
NCT03401385Triple Negative Breast Neoplasms · United States, Japan1Active, not recruitingJan 1, 2028890

How it is read

Names in the registry

  • “Dato-DXd”, 13 entries
  • “Datopotamab deruxtecan”, 5 entries
  • “Datopotamab Deruxtecan”, 5 entries
  • “Datopotamab deruxtecan (Dato-DXd)”, 2 entries
  • “Datopotamab Deruxtecan (Dato-DXd)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.